Japan panel OKs world's first human trial with iPS cells
This article was originally published in Clinica
Executive Summary
Japan has recommended approval of the world's first clinical trial for a regenerative therapy based on induced pluripotent stem (iPS) cells, for the treatment of the most common form of age-related macular degeneration (AMD).